Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib in Combination With Topical Corticosteroids in Adult Patients With Moderate to Severe Atopic Dermatitis BREEZE-AD7

Trial Profile

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib in Combination With Topical Corticosteroids in Adult Patients With Moderate to Severe Atopic Dermatitis BREEZE-AD7

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 09 Jul 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Baricitinib (Primary) ; Corticosteroids; Hydrocortisone; Triamcinolone
  • Indications Atopic dermatitis
  • Focus Registrational; Therapeutic Use
  • Acronyms BREEZE-AD7
  • Sponsors Eli Lilly and Company; Eli Lilly Japan
  • Most Recent Events

    • 01 Jul 2021 Results of an analysis assessing the efficacy of baricitinib plus topical corticosteroids using functional measures of HRQoL, work productivity and life activities, symptom impact and treatment benefit in adults with moderate-to-severe AD with previous inadequate response to topical corticosteroids published in the Journal of the European Academy of Dermatology and Venereology
    • 23 Apr 2021 According to an Eli Lilly media release, these results are being presented virtually at the American Academy of Dermatology's Virtual Meeting Experience (AAD VMX), April 23-25, 2021.
    • 23 Apr 2021 Results of Extended safety analysis of baricitinib 2 mg in the AD clinical program (NCT02576938; NCT03334396; NCT03334422; NCT03428100; NCT03435081; NCT03733301; NCT03334435; NCT03559270), published in the Eli lilly Media Release
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top